Fig. 2
From: Corticosteroid-sparing topical treatment with cyclosporin for juvenile keratoconjunctivitis
Improvement in symptoms of itching and discharge after initiation of CsA-CE treatment at 3 and 6 months compared with baseline in patients with vernal keratoconjunctivitis or blepharitis-related keratoconjunctivitis. Graph showing mean ± SD improvement in the visual analogue scale (VAS) score (0–10) for the symptoms of itching in the VKC group, (a) and in the BKC group (b). Discharge in the VKC group (c) and the BKC group (d). A decrease in VAS score from baseline indicates improvement. * indicates statistically significant (p < 0.05) improvement from baseline.
